The Latest Cardiac and Vascular News
SANTA CLARA, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Kevin Ballinger has joined its Board of Directors and will serve on Shockwave’s Nominating and ESG Committee […]
The Memorial Katy Cardiology Partnership is a part of USHV’s 4th in Houston. NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), a leading national provider of support services to cardiovascular physician practices, announces its partnership with Memorial Katy Cardiology Associates (“Memorial Katy” or “MKCA”), a Houston-based cardiovascular physician practice focused on […]
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights. “2023 has been marked […]
Rouen, France, May 16, 2023 – Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment of cardiovascular diseases, today announces the launch of its latest robotic platform – the R-One+. Robocath will showcase this new solution during the upcoming international EuroPCR conference in Paris (France), from May 16 […]
AccuRhythm AI algorithms now cleared by FDA for the Reveal LINQ ICM; enhancements made to the AF algorithm for the LINQ II ICM DUBLIN, May 16, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT) today announced its AccuRhythm™ AI algorithm technology is the winner of the 7th annual MedTech Breakthrough Awards program as the “Best […]
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., May 15, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the first […]
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical […]
Late-breaking data from DCR4Contrast study presented at EuroPCR 2023 and SCAI 2023 also shows an average reduction in the total number of angiograms obtained during each procedure of 26.3% [1] Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced late-breaking data from the DCR4Contrast […]
U.S. OLPRUVA™ launch progressing ahead of schedule with drug-in-channel now anticipated in mid-June 2023 NEWTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, […]
Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) More than 100 sites activated in 20 countries with the pace of enrollment increasing Sufficiently funded into second half of 2025 WALTHAM, […]
